Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT02245997, this EARLY_PHASE1 trial focuses on Neuroblastoma and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 20 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Oct 2025 — Present [monthly]
Completed EARLY_PHASE1
Phase: NA → EARLY_PHASE1
-
Jun 2025 — Oct 2025 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Nov 2024 — Jun 2025 [monthly]
Active Not Recruiting NA
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
▶ Show 15 earlier versions
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2024 — May 2024 [monthly]
Recruiting NA
-
Dec 2023 — Feb 2024 [monthly]
Recruiting NA
-
Dec 2022 — Dec 2023 [monthly]
Recruiting NA
-
Dec 2021 — Dec 2022 [monthly]
Recruiting NA
-
Jan 2021 — Dec 2021 [monthly]
Recruiting NA
-
Nov 2020 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2020 — Nov 2020 [monthly]
Recruiting NA
-
Jan 2020 — Feb 2020 [monthly]
Recruiting NA
-
Sep 2019 — Jan 2020 [monthly]
Recruiting NA
-
Mar 2019 — Sep 2019 [monthly]
Recruiting NA
-
Jul 2018 — Mar 2019 [monthly]
Recruiting NA
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .